Last edition
News about "Gossamer Bio"
Gossamer Bio Submits First NDA for Seralutinib in PAH
Gossamer Bio has filed an NDA for seralutinib, supported by Phase 3 PROSERA and Phase 2 TORREY study data.
Gossamer Bio | 25/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members